BioPioneers panel on Biotech Funding 2025: Survive, Adapt, Thrive
Join BioPioneers, MBC BioLabs, and SVB for an unfiltered discussion with investors and operators who’ve kept science moving in lean cycles.
Public markets are unforgiving, nearly 40% of biotechs have less than a year of cash left, and VC dollars have tightened to $11.2 B in the first half of 2025, with most of it flowing to later-stage bets. If you’re building (or funding) an early-stage company, you need a new playbook ASAP.
What We’ll Cover
Lean-and-mean operations: slimming pipelines, tranche-based financings, ruthless burn-rate discipline
Creative capital: royalty-backed deals, venture debt, reverse mergers, asset-centric spin-outs
Runway extenders: partnerships, option deals, targeted M&A
Inside the 2025 check-write: what investors must see before they say “yes”
Featured Panelists
Omri Amirav-Drory - General Partner, NFX
Tim Luker - VP, Eli Lilly Ventures
Nancy Stagliano - CEO & Chair, Neuron23
Sophia Lugo - CEO & Chair, Radar Therapeutics
Max Farina - Principal, 5AM Ventures (Moderator)
Agenda
5:30 – 6:30 PM Check-in & Networking
6:30 – 6:45 PM Opening Remarks (BioPioneers, MBC BioLabs, and SVB)
6:45 – 7:30 PM Panel Discussion
7:30 – 8:30 PM Audience Q&A & Networking
Who Should Attend
Founders, CEOs, scientists-turned-entrepreneurs, venture investors, BD leaders, and anyone charting a funding path through 2025’s tight capital markets.
Admission
Free (thanks to our sponsors). Space is limited—requires approval.
Event Terms and Media Release
By registering for this event, you agree to release BioPioneers, its organizers, and all other event hosts from any liability related to your participation. You also consent to being photographed or recorded during the event, with such media potentially used for promotional purposes. Additionally, you agree to receive event updates, newsletters, and invitations from BioPioneers and other event hosts. You may unsubscribe from these communications at any time.